Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
A non-human primate model of Parkinson’s disease based on viral vector mediated overexpression of alpha-synuclein
James Koprich1, Tom Johnston1, John Seibyl2, Ken Marek2, Yilong Ma3, David Eidelberg3, Chuantao Zuo4, Yi Hui Guan4, Jeffrey Kordower5, Susan Fox6 and Jonathan Brotchie1
1Atuka Inc. Toronto, Canada, 2Molecular Neuroimaging, New Haven CT, 3Feinstein Institute for Medical Research, Manhasset, NY, 4PET Center, Huashan Hospital, Shanghai, PRC,
5Rush University Medical Center, Chicago IL, 6Movement Disorders Clinic, University Health Network, Toronto, Canada.
Introduction and Aim • Irrespective of etiology and varying upstream
mechanisms, aSyn deposition is a defining pathological feature of PD.
• Rodent models, transgenic mice and AAV rats, have proven useful in better understanding aSyn function, pathology and biochemistry.
• As in vivo platforms for testing efficacy, the rodent models are currently being, or have been, used to evaluate several classes of therapies ranging from immunotherapy, autophagy enhancing, aggregate clearing, etc.
• Currently lacking in the field is a robust, well-characterized non-human primate model based on aSyn overexpression to optimally transition therapeutic development between rodent and human.
• Our aim in the current study was to develop a primate model of alpha-synucleinopathy that could be used to fill this gap in preclinical drug efficacy testing using a species with a proven track record in preclinical drug screening, the cynomolgus macaque.
Materials & Methods Animals and viral vector delivery. Female cynomolgus macaques (~9 y, ~3 kg) were injected via MRI-guided stereotaxy with 28 µl of 1.7 x 1012 A53T α-syn or a empty vector into the SN over 4 sites within each side of the SN. Behaviour was assessed every month. PET scans (AV-133 and FDG) were conducted every other month. Postmortem measures. Animals were perfused with saline 8 months after surgery and brain portions were dissected fresh or post-fixed. Brains were processed for immuno-labeling and HPLC. Double label immunofluorescence was conducted to reveal tyrosine hydroxylase (TH), human alpha-synuclein or HA to provide detail regarding colocalization. B r i g h t f i e l d m i c r o s c o p y w a s c o n d u c t e d independently on TH and α-synuclein stained sections to reveal axonal morphology and to evaluate protein expression. TH stained sections of the SN will be used for stereological estimation of dopamine neuron numbers
Results
Summary & Conclusions
1. The model is in a position to assess therapeutics aimed at reducing or preventing aSyn accumulation in the nigrostriatal system in a 4 or 8 month timeframe. Endpoints include: striatal neurochemistry and DAT, aSyn load per DA neuron, striatal aSyn levels, number of TH neurons remaining
2. The model shows a behavioural phenotype that includes reduced locomotor activity in the absence of overt disability, representing a pre-motor phase of the early PD patient
3. Robust aSyn expression throughout the nigrostriatal system allows for proof of concept PET studies to screen potential aSyn ligands
aSyn
H AAV-α-syn
p129 aSyn aSyn
TH/ aSyn
TH/ aSyn
TH/ aSyn
AAV1/2 A53T aSyn TH
TH Empty vector control AAV1/2 A53T aSyn
TH
SNpc SNpc
putamen SN SN
SN
putamen
SNpc
Empty vector control
0
20
40
60
spec
ific R
TI-1
21 b
indi
ng (n
Ci/g
tiss
ue)
DATputamen
AAV1/2 Empty Vector
AAV1/2 A53T aSyn
*39% ↓
0
20
40
60
spec
ific R
TI-1
21 b
indi
ng (n
Ci/g
tiss
ue)
DATcaudate
AAV1/2 Empty Vector
AAV1/2 A53T aSyn
*33% ↓
0
50
100
150
dopa
min
e (n
g/m
g pr
otei
n)
dopamineputamen
AAV1/2 Empty Vector
AAV1/2 A53T aSyn
**42% ↓
0
50
100
150
dopa
min
e (n
g/m
g pr
otei
n)
dopaminecaudate
AAV1/2 Empty Vector
AAV1/2 A53T aSyn
0
2
4
6
8
DO
PAC
(ng/
mg
prot
ein)
DOPACputamen
AAV1/2 Empty Vector
AAV1/2 A53T aSyn
*50% ↓
0
2
4
6
8
DO
PAC
(ng/
mg
prot
ein)
DOPACcaudate
AAV1/2 Empty Vector
AAV1/2 A53T aSyn
*34% ↓
DAT putamen
DAT caudate
dopamine putamen
dopamine caudate
DOPAC putamen
DOPAC caudate
0
1
2
3
SUV
r
empty vector controlA53T aSyn
2 4
months postsurgery
6 8
*
baseline
18F AV133 VMAT-2
-1
0
1
2
3
FDG
PrP
sco
re
EVA53T aSyn
2 4
months postsurgery
6 8baseline
FDG PET Parkinson brain
network analysis (PRP)
control aSyn month
-1
+2
+4
+6
+8
18F AV133 VMAT-2
0
1000
2000
3000
4000
activ
ity
empty vector controlA53T aSyn
5 6
months postsurgery
*
7
**
8
*
Absent
Mild
Moderate
Marked
Severe
MPP
rs
Disability(totals, 120 min period)
empty vector controlA53T aSyn
baseline 1 2 3
months postsurgery
4 5 6 7 8
0
10
20
30
time
(s)
empty vector controlA53T aSyn
baseline 1 2 3
months postsurgery
4 5 6 7 8
time to complete mMAP, level D
Distribution of transgene and degenerative changes in the nigrostriatal system produced by exposure to A53T α-synuclein 8 months following injection of AAV1/2
Reduced activity without overt disability
Reductions in striatal DAT and dopamine neurochemistry following exposure to A53T aSyn
AV133 VMAT-2 and FDG PET shows changes over time following exposure to A53T aSyn
33% *
39% *
42% **
50% *
34% *
empty vector control A53T aSyn
empty vector control A53T aSyn